ライフサイエンスコーパス: embryonal

1 ers reported that recessive mutations in the embryonal acetylcholine receptor g subunit (CHRNG) can c

2 ified germline-inactivating mutations in the embryonal acetylcholine receptor gamma subunit (CHRNG) i

3 n of clinical cases revealed that human RMS (embryonal, alveolar, and pleomorphic) harbored human cyt

4 In this Review, we specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcom

5 was absent in almost all human RMS, both for embryonal and alveolar RMS subtypes.

6 es from each major rhabdomyosarcoma subtype (embryonal and alveolar).

7 yosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct clinical, mol

8 Y-DOTATOC; diagnoses included neuroblastoma, embryonal and astrocytic brain tumors, paraganglioma, mu

9 -catenin transcriptional target and multiple embryonal and neural crest malignancies have oncogenic a

10 though well-developed mouse models exist for embryonal and pleomorphic rhabdomyosarcomas, neither a s

11 ferentiated fetal cells, less differentiated embryonal and undifferentiated small cells (SCU) progres

12 Because of small numbers of embryonal arterial cells undergoing EHT and the paucity

13 l groups were elevated in both cotyledon and embryonal axis.

14 e of the resemblance of the spheroids to the embryonal blastocyst and their resistance to traditional

15 nerated spheroids in vitro that resemble the embryonal blastocyst.

16 ne profile resemblance of these spheroids to embryonal blastocysts, we wondered whether they might ex

17 d, constitutively active Notch1 or Notch2 in embryonal brain tumor cell lines caused antagonistic eff

18 In a pediatric embryonal brain tumor tissue microarray, we observed an

19 of medulloblastoma, a histologically similar embryonal brain tumor.

20 with deregulated E2F1 show the formation of embryonal brain tumors such as medulloblastoma, choroid

21 age in a group of medulloblastomas and other embryonal brain tumors using differential PCR.

22 Pediatric embryonal brain tumors with multilayered rosettes demons

23 T gene amplification is relatively common in embryonal brain tumors, and that increased expression of

24 of Notch2, we analyzed its gene dosage in 40 embryonal brain tumors, detecting an increased copy numb

25 in both nonneoplastic neural stem cells and embryonal brain tumors, such as medulloblastoma, which a

26 quantitative PCR to measure hTERT mRNA in 50 embryonal brain tumors.

27 atric patients previously operated on for an embryonal brain tumour (13 patients prospectively diagno

28 alamocortical tract involvement in childhood embryonal brain tumour patients who developed posterior

29 Neuroblastoma, an embryonal cancer of neural crest origin, shows metastase

30 Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS)

31 tivity directs initiation and progression of embryonal cancer.

32 yndrome associated with an increased risk of embryonal cancers in childhood.

33 ann syndrome (BWS), which increases risk for embryonal cancers, including Wilms tumor.

34 ncer-predisposition syndrome associated with embryonal cancers, macroglossia, macrosomia, ear pits or

35 (NSE), the latter including the pluripotent embryonal carcinoma (EC) and its differentiated derivati

36 Pluripotent cells within embryonal carcinoma (EC) can differentiate in vivo or in

37 used the well-characterized pluripotent P19 embryonal carcinoma (EC) cell culture model of neuro-ect

38 e to all-trans retinoic acid (RA), the human embryonal carcinoma (EC) cell line, NT2/D1, differentiat

39 Using human embryonal carcinoma (EC) cells as bait, approximately 3

40 Embryonal carcinoma (EC) cells have served as a model to

41 et of neuroectodermal differentiation in P19 embryonal carcinoma (EC) cells three independent techniq

42 OCT4 levels and increases the resistance of embryonal carcinoma (EC) cells to cisplatin and bleomyci

43 therapy, and testicular cancer-derived human embryonal carcinoma (EC) cells undergo a p53-dominant tr

44 silenced genes in cancer cells; however, in embryonal carcinoma (EC) cells, CBX7 can initiate stable

45 bryonic stem (ES) cells and can give rise to embryonal carcinoma (EC) cells, the stem cells of testic

46 erentiated cells, but not in the parental F9 embryonal carcinoma (EC) cells.

47 wn that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with

48 ed mouse embryonic stem (ES) cells and mouse embryonal carcinoma (EC) lines.

49 de of Noxa reduced the apoptotic response of embryonal carcinoma (EC) NTERA2 cells to cisplatin.

50 us GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (

51 t there is a subgroup of NSGCT patients with embryonal carcinoma (with or without other histologies)

52 ity and trophoblast differentiation of mouse embryonal carcinoma and embryonic stem cells.

53 Presence of vascular invasion together with embryonal carcinoma and rete testis invasion in the test

54 We further identified the embryonal carcinoma antigen podocalyxin-like protein 1 (

55 In the embryonal carcinoma cell line NT2/D1, ectopic DeltaN-p63

56 ct4 gene locus in retinoic acid (RA)-treated embryonal carcinoma cell line P19, which involves recept

57 Incubation of a human embryonal carcinoma cell line with NMM reduces its stem

58 Both species are repressed when the human embryonal carcinoma cell line, NT2/D1, is induced to dif

59 clude two regions of promoter activity in an embryonal carcinoma cell line, Tera2EC.

60 ell lines, five normal human tissues, and an embryonal carcinoma cell line.

61 significantly greater levels in human ES and embryonal carcinoma cell lines than in control samples.

62 ines showed many similarities with the human embryonal carcinoma cell samples and more distantly with

63 the Hoxa1, RARbeta2, and Cyp26A1 RAREs in F9 embryonal carcinoma cells (teratocarcinoma stem cells) d

64 predominant form in embryonic stem cells and embryonal carcinoma cells and can also be detected from

65 lated during neuronal differentiation in P19 embryonal carcinoma cells and epigenetic changes play an

66 ted knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells c

67 rget of GATA-6 regulation in differentiating embryonal carcinoma cells and that, in vivo, the express

68 These studies employed F9 embryonal carcinoma cells and their differentiated cells

69 protein synthesis-independent manner in P19 embryonal carcinoma cells by inactivation of NF-kappa B.

70 wn of Cripto-1 expression in human and mouse embryonal carcinoma cells desensitized the ligand-induce

71 FoxA proteins are induced when F9 embryonal carcinoma cells differentiate into visceral en

72 rmation of primitive endoderm from mouse P19 embryonal carcinoma cells in response to retinoic acid,

73 neural cells derived from embryonic stem and embryonal carcinoma cells in vitro and neural stem cells

74 st cancer cells and suppressed the growth of embryonal carcinoma cells in vitro.

75 Studies of miR-125b function in mouse P19 embryonal carcinoma cells induced to develop into neuron

76 of the expressing differentiated cells with embryonal carcinoma cells or by treatment of the differe

77 Removal of endogenous OAZ from pluripotent embryonal carcinoma cells prevents the induction of Smad

78 Here, we report that human embryonal carcinoma cells proliferate and produce differ

79 that overexpressing Hoxa2 in cultures of P19 embryonal carcinoma cells reduced the frequency of spont

80 ion of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cispla

81 Embryonal carcinoma cells represent the pluripotent enti

82 rentiation, whereas studies with pluripotent embryonal carcinoma cells suggest that this pathway prom

83 ed large sets of genes in embryonic stem and embryonal carcinoma cells that are associated with the t

84 tutive levels of this BH3-only protein prime embryonal carcinoma cells to undergo rapid and massive a

85 o DNA methylation-associated inactivation in embryonal carcinoma cells were transfected into differen

86 sttranscriptionally in embryonic stem cells, embryonal carcinoma cells, and primary tumors.

87 cardiomyocyte differentiation in pluripotent embryonal carcinoma cells, and we show that this involve

88 d in mES cells and in Ntera-2 or NCCIT human embryonal carcinoma cells, as compared with cells growin

89 In P19 mouse embryonal carcinoma cells, expression of the MOR was gre

90 we show that in mouse embryoid bodies or F9 embryonal carcinoma cells, RARs occupy a large repertoir

91 We have studied the function of LINC in F9 embryonal carcinoma cells, which are distinguished by a

92 nd murine mammary stem/progenitor cells, and embryonal carcinoma cells.

93 ouse embryonic stem (mES) cells and in human embryonal carcinoma cells.

94 erum/cytokine-free expansion of leukemic and embryonal carcinoma cells.

95 ng RA-driven differentiation of human NT2/D1 embryonal carcinoma cells.

96 ctodermal differentiation of pluripotent P19 embryonal carcinoma cells.

97 colocalizing with OCT4 in Ntera2 testicular embryonal carcinoma cells.

98 ons of dorsal root ganglion (DRG) and in P19 embryonal carcinoma cells.

99 platin in testicular germ cell-derived human embryonal carcinoma cells.

100 vity that accompanies the differentiation of embryonal carcinoma cells.

101 s the specificity of RNA interference in p19 embryonal carcinoma cells.

102 f RA-induced neuronal differentiation in p19 embryonal carcinoma cells.

103 fferentiation and cell cycle arrest in human embryonal carcinoma cells.

104 ribosomal frameshifting signal of the mouse embryonal carcinoma differentiation regulated (Edr) gene

105 protein-coupled receptor is regulated during embryonal carcinoma differentiation.

106 Embryonal carcinoma is a model of embryonic development

107 ates 9 of 15 genes in this pathway in the F9 embryonal carcinoma model and 11 of 15 pathway genes in

108 When comparing undifferentiated human embryonal carcinoma NT2- cells and differentiated NT2N n

109 of neural progenitor cells, using the mouse embryonal carcinoma P19 cell line as a model system.

110 id receptor (KOR) gene is expressed in mouse embryonal carcinoma P19 cells and induced by retinoic ac

111 Using mouse embryonal carcinoma P19 cells as a neural differentiatio

112 X protein levels are also increased in mouse embryonal carcinoma P19 cells during retinoic acid (RA)-

113 Stimulation of endogenous EphB1 in embryonal carcinoma P19 cells with its ligand ephrinB1 i

114 knockdown Smn gene expression in the murine embryonal carcinoma stem cell line P19, which can be dif

115 We used an embryonal carcinoma stem cell model and show here that (

116 Cs across species and between human ESCs and embryonal carcinoma stem cells suggest that while plurip

117 r the differentiation of cultured P19 murine embryonal carcinoma stem cells to beating cardiac myocyt

118 quired for the differentiation of murine P19 embryonal carcinoma stem cells to beating cardiac myocyt

119 ed for 95 previously untreated patients with embryonal carcinoma with or without other germ cell comp

120 Comparison of embryonal carcinoma with seminomas revealed relative ove

121 -cm tumor that was 95% yolk sac tumor and 5% embryonal carcinoma, and retroperitoneal lymph node diss

122 erentiated human GCTs, such as seminomas and embryonal carcinoma, but not in normal testis or in diff

123 ion of several stem cell-associated genes in embryonal carcinoma, including several core "stemness" g

124 Required histology included yolk sac, embryonal carcinoma, or choriocarcinoma.

125 btypes included immature teratoma, seminoma, embryonal carcinoma, yolk sac tumor, and choriocarcinoma

126 These results show that human embryonal carcinoma-derived progeny interact with mouse

127 ith good clinical prognosis in patients with embryonal carcinoma.

128 Pluripotent embryonal carcinomas (EC) are the malignant counterparts

129 Embryonal carcinomas (EC) comprise a subset of TGCTs tha

130 the pluripotent cells (embryonic stem cells, embryonal carcinomas and induced pluripotent cells).

131 that exhibited coordinated overexpression in embryonal carcinomas and seminomas, which included the k

132 lain the differences in pluripotency between embryonal carcinomas and seminomas.

133 and nonseminomas, which include pluripotent embryonal carcinomas as well as other histologic subtype

134 d malignant tumors, with yolk sac tumors and embryonal carcinomas positive for alpha-fetoprotein, cyt

135 t has implications for both undifferentiated embryonal cells and for cancers in which pocket protein

136 ctors and homeobox proteins predominating in embryonal cells and glycoproteins and immunoglobulin-rel

137 some Suz12 target genes are bound by OCT4 in embryonal cells and suggest that OCT4 maintains stem cel

138 otein kinase p38 in mouse F9 teratocarcinoma embryonal cells.

139 m impaired differentiation of neuronal crest embryonal cells.

140 Embryonal central nervous system (CNS) tumors, which com

141 ally led to the proposal that tumors take on embryonal characteristics, the so called embryonal theor

142 In the present study, we show that human embryonal CNS tumor cell lines and surgical tumor specim

143 ts younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg.

144 gnancy with multifunctional effects in human embryonal CNS tumors.

145 esis is unknown, their relationship to other embryonal CNS tumours is debated, and patients' response

146 Doxycycline (Dox) was administered from embryonal day 14 to postnatal day 7, and lungs were stud

147 sL) overexpression, treated with Dox between embryonal day 15 and postnatal day 3, served as a model

148 rise of embryonic transgene expression until embryonal day 18, with an abrupt postnatal decline.

149 tnatal day 7, and lungs were studied between embryonal day 19 and postnatal day 21.

150 n many important cellular processes, notably embryonal development and cellular differentiation.

151 en neighboring cells that are crucial during embryonal development and in adults.

152 n tumors, may be associated with the special embryonal development morphologic transition of this mal

153 Embryonal (ERMS) and alveolar (ARMS) are the two major R

154 n occurs as two major histological subtypes, embryonal (ERMS) and alveolar (ARMS).

155 rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors.

156 negative associations between later life and embryonal expression profiles.

157 Here, we examine the growth pattern of embryonal fibroblasts derived from Lsh-/- mice.

158 Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53,

159 ant role in mitotic defects of Lsh-/- murine embryonal fibroblasts, possibly by altering chromatin st

160 reased risk of developing hepatoblastoma, an embryonal form of liver cancer, suggesting that Wnt affe

161 levels of tropoelastin mRNA were low during embryonal growth and increased substantially in neonates

162 eta-catenin and differentiation status, with embryonal hepatoblastomas expressing full-length beta-ca

163 In rhabdomyosarcoma, genitourinary site and embryonal histology confer a relatively favorable progno

164 Patients with embryonal histology had a significantly better 5-year EF

165 The combination of embryonal histology with two or fewer metastatic sites i

166 Eight patients had embryonal histology, and 24 patients had alveolar histol

167 f they had two or fewer metastatic sites and embryonal histology.

168 , age less than 10 years, low IRS group, and embryonal histology.

169 epitope tagging in stably transfected human embryonal kidney (HEK) 293 cells, immunoaffinity purific

170 Human embryonal kidney 293 alphaIIbbeta3 cells overexpressing

171 uclear antigen (LANA) was expressed in human embryonal kidney 293 cells and a bone marrow stromal cel

172 A) negatively regulate the adhesion of human embryonal kidney 293 cells expressing alpha(IIb)beta(3)

173 Ib)beta(3) in resting platelets and in human embryonal kidney 293 cells expressing alpha(IIb)beta(3).

174 PAR-/-murine embryonic fibroblasts and human embryonal kidney 293 cells, SuPAR functions as a partial

175 moter methylation arrays, we show that human embryonal kidney cells over-expressing WT1 acquire DNA m

176 uced DNMT3A in Wilms' tumour cells and human embryonal kidney-derived cell lines.

177 eptors in mouse embryos often leads to early embryonal lethality.

178 Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithe

179 Neuroblastoma is a neural crest-derived embryonal malignancy, which accounts for 13% of all pedi

180 gradually changes from a fine network in the embryonal mass cells to thick cables in the suspensor ce

181 The microtubule arrays appear normal in the embryonal mass cells, but the microtubule network is par

182 or cell types: the meristematic cells of the embryonal mass on one pole and the terminally differenti

183 es and F-actin changes successively from the embryonal mass towards the distal end of the embryo susp

184 Pa ESP was expressed in the proliferating embryonal mass, while it was absent in the suspensor cel

185 , Cripto-1 is enriched in a subpopulation of embryonal, melanoma, prostate, and pancreatic cancer cel

186 netic alterations associated with the unique embryonal morphology of nonseminomatous subtypes of test

187 formed rhabdomyosarcoma-like tumors with an embryonal morphology, capable of invasion and metastasis

188 This embryonal neoplasm often encases vascular structures and

189 volved in the progression of these malignant embryonal neoplasms.

190 asomotor nerve cells, which originate in the embryonal neural crest can lead to their formation.

191 Neuroblastoma arises from the embryonal neural crest secondary to a block in different

192 in low-stage neuroblastoma tumors and normal embryonal neuroblasts, but reduced in late-stage neurobl

193 quiescently HCMV-infected human pluripotent embryonal NTera2 cells (NT2) to model HCMV reactivation,

194 ase using the terms neoplasms, germ cell, or embryonal or testicular neoplasms restricted to humans,

195 ges: pediatric solid tumors are typically of embryonal origin, whereas adult tumors are usually carci

196 growth of two different rhabdomyosarcoma (RD embryonal P = 0.00008; Rh30 alveolar P = 0.0002) cell li

197 During embryonal period, complete obliteration of the urachus a

198 e isoform cross-linking collagen IV in mouse embryonal PFHR-9 cells.

199 ant flow in the aorta and extending into the embryonal-placental circulation, which was evident after

200 actor Hnf4alpha leads to derepression of the embryonal proto-oncogene Hmga2 in Nkx2-1-negative tumors

201 n of the invadopodia component Tks5long, the embryonal proto-oncogene Hmga2, and the epithelial-to-me

202 reviously by Oomizu et al to be expressed in embryonal rat epidermis at the mRNA level.

203 One million alveolar (Rh30) and embryonal (RD) rhabdomyosarcoma cells with stably transf

204 ll carcinoma (BCC), medulloblastoma (MB) and embryonal rhabdhomyosarcoma (eRMS), three principle tumo

205 Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyo

206 Embryonal Rhabdomyosarcoma (ERMS) and Undifferentiated P

207 y resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-fre

208 Embryonal rhabdomyosarcoma (ERMS) is a common pediatric

209 Embryonal rhabdomyosarcoma (ERMS) is a devastating cance

210 Embryonal rhabdomyosarcoma (ERMS) is an aggressive pedia

211 fusion protein PAX3-FOXO1 or PAX7-FOXO1, and embryonal rhabdomyosarcoma (ERMS), which is genetically

212 port that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS).

213 n (VA) for patients with subset-one low-risk embryonal rhabdomyosarcoma (ERMS; stage 1/2 group I/II E

214 he spontaneous development of muscle-derived embryonal rhabdomyosarcoma (RMS) after 1 year of age.

215 ntreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarco

216 activity as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhab

217 The childhood cancer embryonal rhabdomyosarcoma can arise in tissue without s

218 chanisms that prevent MyoD activity in human embryonal rhabdomyosarcoma cells.

219 e a cell of origin for Sonic Hedgehog-driven embryonal rhabdomyosarcoma in an adipocyte-restricted co

220 tiation block in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold prom

221 A diagnosis of embryonal rhabdomyosarcoma was made.

222 A KRAS(G12D)-induced zebrafish embryonal rhabdomyosarcoma was then used to assess the t

223 a secondary tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients were alive at

224 nt of lineage (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma), are particularly sensitive

225 partitioning of tumour-propagating cells in embryonal rhabdomyosarcoma, emergence of clonal dominanc

226 ic variegated aneuploidy, including two with embryonal rhabdomyosarcoma, we identified truncating and

227 Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostat

228 on-arrested and proliferative phenotypes for embryonal rhabdomyosarcoma.

229 potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.

230 associated with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS).

231 atous testicular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas, and in 1 of 266 epithelial

232 RMS (age 21 years or younger) or metastatic embryonal RMS (age 2 to 10 years) were enrolled between

233 ntly observed in alveolar RMS (ARMS) than in embryonal RMS (ERMS) (81% v 32%, respectively; P < .001)

234 urvival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, g

235 In embryonal RMS (eRMS), HO-1 expression was induced by Pax

236 arcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, a

237 There are two main subgroups, embryonal RMS and alveolar RMS (ARMS).

238 und in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively.

239 e environment for spontaneous development of embryonal RMS associated with mutation of p53 and mutati

240 as necessary for growth of alveolar RMS and embryonal RMS both in vitro and in vivo.

241 rthermore, transfer of a PAX3-FKHR gene into embryonal RMS cell activates CXCR4 expression.

242 in RNA (shRNA) library in an alveolar and an embryonal RMS cell line.

243 MS cells express higher levels of c-MET than embryonal RMS cell lines and "home/seed" better into bon

244 Six human alveolar and three embryonal RMS cell lines were examined.

245 ooperate to induce apoptosis in alveolar and embryonal RMS cells in a highly synergistic fashion (com

246 e embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); al

247 MS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free su

248 Treatment strata were embryonal RMS, stage 2/3, group III (33%); embryonal RMS

249 For embryonal RMS, there was no statistically significant di

250 RLND alters prognosis for alveolar but not embryonal RMS.

251 a (n = 2), hamartoma (n = 1), and metastatic embryonal sarcoma (n = 1).

252 actor critical for the pluripotency of human embryonal stem (ES) and induced pluipotency stem (IPS) c

253 tween pathways that regulate pluripotency in embryonal stem (ES) cells and oncogenesis.

254 MARY-X spheroids expressed embryonal stem cell markers including stellar, rex-1, ne

255 wn Oct4 and Stat3 systems required for early embryonal stem cell potency and self-renewal.

256 isms, being required for the self-renewal of embryonal stem cells in response to leukemia inhibitory

257 rowth as well as regenerative therapies with embryonal stem cells.

258 st SOX2, a gene critical for self-renewal in embryonal stem cells.

259 type AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively.

260 strong risk of metastasis compared with the embryonal subtype (ERMS).

261 ines representative of both the alveolar and embryonal subtypes.

262 ion, i.e. the canonical pathway, in mouse F9 embryonal tetratocarcinoma cells expressing rat Frizzled

263 o oncogenic chromosome dynamics and that the embryonal theory for cancer cell growth/proliferation is

264 on embryonal characteristics, the so called embryonal theory of cancer.

265 While there is a long history of targeting embryonal tissues toward cancer vaccines, recent identif

266 viously, we observed expression of Oct-4, an embryonal transcriptional regulator, in osteosarcoma cel

267 ule network is partially disorganised in the embryonal tube cells and the microtubules disrupted in t

268 spensor cells on the other, separated by the embryonal tube cells.

269 ally invasive or metastatic tumors, in which embryonal tumor cells are EGFR-negative, while SCU cells

270 Conversely, at an older age, mice escaping embryonal tumor formation present with malignant gliomas

271 et consistent with a time-limited window for embryonal tumor initiation.

272 toma and neuroblastoma exemplify the current embryonal tumor model.

273 lopment and the medulloblastoma, a malignant embryonal tumor of the cerebellum, have proven especiall

274 oter hypermethylation in medulloblastoma, an embryonal tumor of the cerebellum.

275 Medulloblastoma is an embryonal tumor thought to arise from the granule cell p

276 Hepatoblastoma is a rare embryonal tumor with unknown etiology.

277 ulloblastoma/primitive neuroectodermal tumor/embryonal tumor, 17 had malignant astrocytoma, nine had

278 after diagnosis and treatment of a pediatric embryonal tumor.

279 normal development, supporting the model of embryonal tumorigenesis.

280 or of unknown cause, is not associated with embryonal tumors and cells from these individuals show m

281 Pediatric patients with CNS embryonal tumors are at high risk for treatment-related

282 Genomic analysis shows that embryonal tumors have more structural and copy number va

283 unger than 3 years with primary intracranial embryonal tumors is now in progress.

284 are highly aggressive, poorly differentiated embryonal tumors occurring predominantly in young childr

285 selective radioimmunoconjugates specific for embryonal tumors of childhood are currently being active

286 Embryonal tumors with multilayered rosettes (ETMRs) are

287 Intraocular medulloepitheliomas and embryonal tumors with multilayered rosettes of the brain

288 RIP13 or BUB1B mutations have a high risk of embryonal tumors, and here we show that their cells disp

289 c tumors representing sarcomas, extracranial embryonal tumors, brain tumors, hematologic malignancies

290 ne abdominal wall defects, macroglossia, and embryonal tumors, is a model for understanding the relat

291 y have utility for this and other MYC-driven embryonal tumors.

292 en younger than 3 years with newly diagnosed embryonal tumors.

293 Medulloblastoma is the most common embryonal tumour in children.

294 Wilms tumour is an embryonal tumour of childhood that closely resembles the

295 Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous s

296 Embryonal tumours of the central nervous system (CNS) re

297 Choriocarcinomas are embryonal tumours with loss of imprinting and hypermethy

298 gnificantly influenced by histology (47% for embryonal v 34% for all others, P =.026) and increasing

299 cle-like differentiation of RMS cells of the embryonal variant.

300 Growth of human embryonal WI38 fibroblasts is highly dependent on fibrob